| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC0875 | Balanol | Potent ATP-competitive inhibitor of Protein Kinase C (PKC) and Protein Kinase A (PKA) |
|
| DCC0876 | Balofloxacin Hydrate | Antibacterial; Antimicrobial; Inhibitor of DNA gyrase and intracellular accumulation of quinolones |
|
| DCC0877 | Bam Complex Inhibitor 14 | Novel BAM complex inhibitor, interferring with BamA-related processes and affect folding and insertion of OMPs |
|
| DCC0878 | Bam Complex Inhibitor 2 | Novel BAM complex inhibitor, interferring with BamA-related processes and affect folding and insertion of OMPs |
|
| DCC0879 | Banoxantrone Dihydrochloride | Hypoxia-activated prodrug of topoisomerase II inhibitor |
|
| DCC0880 | baq Diphosphate | Antimalarial; Novel Chloroquine analog against Chloroquine-Resistant Parasites |
|
| DCC0881 | Barbatolic Acid | Natural anti-breast cancer and anti-angiogenic agent |
|
| DCC0882 | Barbigerone | Inhibitor of tumor angiogenesis, growth and metastasis in melanoma |
|
| DCC0883 | Barixibat | Bile acid transporter inhibitor |
|
| DCC0884 | Bas00127538 | The first small molecule inhibitor of Lipid II |
|
| DCC0885 | Bashy-btz 5 | Novel fluorescent Bortezomib-GV1001 conjugate for monitoring the delivery of the proteasome inhibitor bortezomib (Btz) to HT-29 cancer cells, exhibiting an improved cytoplasmic availability |
|
| DCC0886 | Bauerine C | Anticancer agent; inhibitor of BMP2K (BIKE) and DRAK1 |
|
| DCC0887 | Bavisant dihydrochloride hydrate | Bavisant dihydrochloride hydrate (JNJ31001074AAC) is an orally active, potent, brain-penetrating and highly selective antagonist of the histamine H3 receptor. Bavisant dihydrochloride hydrate can be used for attention-deficit hyperactivity disorder (ADHD) research. |
|
| DCC0888 | Bax Inhibitor P5 | Novel cell-permeable synthetic peptide inhibitor of Bax, blocking apoptosis |
|
| DCC0889 | Bay 27-9955 | Novel glucagon receptor antagonist |
|
| DCC0890 | Bay-0361 | Negative control for BAY-091 |
|
| DCC0891 | Bay1143269 | Novel MNK1 inhibitor, targeting oncogenic protein expression and showing potent anti-tumor activity |
|
| DCC0892 | Bay-173 | Negative control for BAY-3153 |
|
| DCC0893 | Bay1830839 | Novel potent interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor (IC 50 of 3 nM) |
|
| DCC0894 | Bay-364 | Negative control for BAY299 |
|
| DCC0895 | Bay-369 | Control compound for BAY-598, a novel potent inhibitor of SMYD2 |
|
| DCC0896 | Bay-438 | Novel allosteric MEK inhibitor with long half-lives, high bioavailabilities, low brain penetration potential and high efficacy in a K-Ras-mutated A549 xenograft model |
|
| DCC0897 | Bay-4900 | Negative control for BAY-549 |
|
| DCC0898 | Bay-677 | Negative control for BAY-678, a potent and selective human neutrophil elastase (HNE) inhibitor |
|
| DCC0899 | Bay-846 | Novel allosteric MEK inhibitor with long half-lives, high bioavailabilities, low brain penetration potential and high efficacy in a K-Ras-mutated A549 xenograft model |
|
| DCC0900 | Bay-9897 | Negaitve control for BAY-390 |
|
| DCC0901 | Bay-acc001 | Novel potent and selective acetyl-CoA carboxylase (ACC) inhibitor |
|
| DCC0902 | Bay-acc002 | Novel potent and selective acetyl-CoA carboxylase (ACC) inhibitor, blocking WNT3A lipidation, secretion, and signaling |
|
| DCC0903 | Bazinaprine | Selective inhibitor of type A monoamine oxidase with dopaminergic properties |
|
| DCC0904 | Bb-0300674 | Novel inhibitor of prion replication |
|
